Table 1.
Study ID | Study design | Country | Sex (male/female) | Age | Methods (comparison) | Anaesthesia technique | Dosage (experiment/control) | Recording time | Outcome |
---|---|---|---|---|---|---|---|---|---|
Abdulwahab5 | Crossover | USA | 6/12 | 18–65 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in mandibular first molars | Infiltration | 0.9 ml | Every minute for the first 20 minutes after injection using EPT | SRA |
Schleder16 | Crossover | USA | 40/35 | 20–31 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in mandibular first premolar | Periodontal ligament injection | 1.82 ml | 2,4,10,30,45 minutes using EPT | SRA, PTI, AE |
Mason17 | Crossover | USA | 31/29 | 19–43 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline/2% lidocaine + 1:50,000 adrenaline in maxillary lateral incisor and first molars | Infiltration | 1.8 ml | 3-min cycles for 60 minutes at 1 minutes after injection using EPT | SRA, OTP |
Lawary18 | Crossover | USA | 30/30 | 21–31 | 2% Mepivacaine + 1:20,000 levonordefrin with 2% lidocaine + 1:100,000 adrenaline in maxillary teeth | Infiltration | 1.8 ml | 2-minute cycles for 60 minutes at 1 minute after injection using EPT | SRA |
Berberich19 | Crossover | USA | 34/6 | 23–33 | 3% mepivacaine with 2% lidocaine + 1:100,000 adrenaline/2% lidocaine + 1:50,000 adrenaline in maxillary teeth | Intraoral, infraorbital nerve block | Unclear | 4-minute cycles for 60 min at 1–4 min after injection using EPT | SRA, PTI, PTP, OTP |
Forloine20 | Crossover | USA | 27/23 | 18–57 | 3% mepivacaine with 2% lidocaine + 1:100,000 adrenaline in maxillary teeth | Maxillary block | 3.6 ml | 4-minute cycles for 60 minutes at 1–4 minutes after injection using EPT | SRA, PTI, PTP, AE |
McLean21 | Crossover | USA | 24/6 | 24–43 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in mandibular teeth | IANB | 1.8 ml | 3-minute cycles for 50 minutes at 1–3 minutes after injection using EPT | SRA, OTP |
Hinkley22 | Crossover | USA | 19/11 | 23–42 | 2% Mepivacaine + 1:20,000 levonordefrin with 2% lidocaine + 1:100,000 adrenaline in mandibular teeth | IANB | 1.8 ml | 3-minute cycles for 50 minutes at 1–3 minutes after injection using EPT | SRA, OTP |
Replogle23 | Crossover | USA | 25/17 | 18–39 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in mandibular molars | IO | 1.8 ml | 2-minute cycles for 60 minutes at 1–2 minutes after injection using EPT | SRA, PTI, PTP |
Burns24 | Cross-over | USA | 20/20 | 19–47 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in maxillary central incisors, lateral incisors and canines using computer-assisted injection system | P-ASA | 1.4 ml | 4-minute cycles for 72 minutes at 1–4 minutes after injection using EPT | SRA |
Bradley25 | Parallel | Australia | 131/128 | 5–14 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth | Infiltration and IANB | 1.8 ml & 0.8–3.6 ml | Unclear | SRA |
Cohen26 | Parallel | USA | Unclear | Unclear | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in mandibular teeth diagnosed with irreversible pulpitis | IANB | 1.8 ml | 1 minute after injection using DDM | SRA |
Kramp27 | Parallel | USA | Totally 150 | Unclear | 2% Mepivacaine + 1:20,000 levonordefrin with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth | Infiltration and IANB | 0.3–0.6 ml for infiltration and 1.8 ml for IANB | Unclear | PTI |
Nusstein28 | Crossover | USA | 20/20 | 18–65 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth using the Wand Plus system | P-ASA | 1.4 ml | 4-minute cycles for 72 minutes after injection using the EPT | PTI, PTP, AE |
Replogle29 | Crossover | USA | 25/17 | 18–39 | 3% Mepivacaine with 2% lidocaine + 1:100,000 adrenaline | IO | 1.8 ml | 2-minute cycles for 30 minutes after injection using EPT | AE |
Shi30 | Parallel | China | 55/72 | 20–65 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth | Infiltration | 1.8 ml | 1, 3, 5 minutes after injection using the EPT | SRA, AE, OTP |
Chen31 | Parallel | China | 11/7 | 18–60 | Compared 2% mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary teeth diagnosed with pulpitis or deep caries | Infiltration | 1.8 ml | At 1, 3, 5 minutes after injection using the EPT | SRA, AE, OTP |
Wu32 | Parallel | China | 17/43 | 12–70 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth diagnosed with irreversible pulpitis | Infiltration and IANB | 1.8 ml/5.0 ml | Unclear | SRA |
Li33 | Parallel | China | 38/32 | 60–72 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth diagnosed with irreversible pulpitis | Infiltration | 1.8 ml/5.0 ml | 7 minutes after injection | SRA, AE |
Dong34 | Parallel | China | 73/134 | Mean 37.4 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary molars diagnosed with acute pulpitis, chronic pulpitis. | Infiltration and IANB | 1.8 ml/5.0 ml | Unclear | SRA |
Liu35 | Parallel | China | 39/41 | 23–62 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth that need pulp therapy or extraction | Infiltration and IANB | 1.7 ml/5.0 ml | Unclear | SRA |
Xing36 | Parallel | China | Unclear | Unclear | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth diagnosed with irreversible pulpitis or periodontal disease | Infiltration and IANB | 0.9–1.8 ml/5.0 ml | At 1, 2, 5 minutes after injection | SRA |
Luo37 | Parallel | China | 372/0 | 20–40 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary molars that need extraction | Infiltration and maxillary block | 1.8 ml/5.0 ml | Unclear | SRA |
Ge38 | Parallel | China | Totally 57 | Unclear | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in mandibular molars diagnosed with chronic pulpitis | Infiltration and IANB | 1.8 ml/5.0 ml | Unclear | SRA, PTI |
Xuan39 | Parallel | China | 51/45 | 20–60 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth that need prosthodontic therapy | Infiltration and IANB | 1.8 ml/4.0 ml | Unclear | SRA, PTI |
He40 | Parallel | China | 151/241 | 12–70 | 2% Mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth diagnosed with irreversible pulpitis | Infiltration and IANB | 1.8 ml/5.0 ml | Unclear | SRA, AE |
Zhou41 | Parallel | China | 43/57 | 23–76 | 2% mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in mandibular teeth that need pulp therapy or extraction | IANB | 1.5 ml/5.0 ml | Unclear | SRA |
Jin42 | Parallel | China | Totally 360 | 6–78 | 2% mepivacaine + 1:100,000 adrenaline with 2% lidocaine + 1:100,000 adrenaline in maxillary and mandibular teeth diagnosed with pulpitis or tooth trauma | Infiltration and IANB | 1.8 ml/5.0 ml | Unclear | SRA |
IANB, inferior alveolar nerve block; SRA, success rate of anaesthesia; OTP, onset time of pulpal aesthesia; PTI, pain ratings for injection phase; PTP, pain ratings for postinjection phase; AE, adverse events; IO, intraosseous injection; P-ASA, palatalanterior superior alveolar injection.